Unknown

Dataset Information

0

COVID-19-Associated Pulmonary Fungal Infection among Pediatric Cancer Patients, a Single Center Experience.


ABSTRACT: Patients with COVID-19 are at risk of developing secondary complications such as invasive pulmonary aspergillosis and mucormycosis. This is a retrospective study including all cancer children diagnosed with COVID-19-associated pulmonary fungal infection (CAPFI) during the period 2020-2021. A total of 200 patients were diagnosed with COVID-19, out of which 21 (10%) patients were diagnosed with CAPFI, 19 patients (90%) with COVID-aspergillosis (CAPA), and 2 (10%) patients with COVID-mucormycosis (CAM). Patients with CAPFI were classified using the "2020 ECMM/ISHAM consensus criteria"; proven in 2 (10%) patients, probable in 12 (57%), and possible in 7 (33%) patients. Although the hematological malignancy patients were already on antifungal prophylaxis, breakthrough fungal infection was reported in 16/21 (75%), 14 (65%) patients had CAPA while on echinocandin prophylaxis, while 2 (10%) patients had CAM while on voriconazole prophylaxis. Overall mortality was reported in 8 patients (38%) while CAPFI-attributable mortality was reported in 4 patients (20%). In conclusion, clinicians caring for pediatric cancer patients with COVID-19 should consider invasive pulmonary fungal infection, even if they are on antifungal prophylaxis, especially with worsening of the clinical chest condition. A better understanding of risk factors for adverse outcomes may improve clinical management in these patients.

SUBMITTER: Madney Y 

PROVIDER: S-EPMC9409978 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

COVID-19-Associated Pulmonary Fungal Infection among Pediatric Cancer Patients, a Single Center Experience.

Madney Youssef Y   Shalaby Lobna L   Hammad Mahmoud M   Elanany Mervat M   Hassan Reem R   Youssef Ayda A   Abdo Ibrahim I   Zaki Abeer A   Khedr Reham R  

Journal of fungi (Basel, Switzerland) 20220815 8


Patients with COVID-19 are at risk of developing secondary complications such as invasive pulmonary aspergillosis and mucormycosis. This is a retrospective study including all cancer children diagnosed with COVID-19-associated pulmonary fungal infection (CAPFI) during the period 2020-2021. A total of 200 patients were diagnosed with COVID-19, out of which 21 (10%) patients were diagnosed with CAPFI, 19 patients (90%) with COVID-aspergillosis (CAPA), and 2 (10%) patients with COVID-mucormycosis (  ...[more]

Similar Datasets

| S-EPMC8578026 | biostudies-literature
| S-EPMC8618928 | biostudies-literature
| S-EPMC11365680 | biostudies-literature
| S-EPMC10185933 | biostudies-literature
| S-EPMC7928619 | biostudies-literature
| S-EPMC8513511 | biostudies-literature
| S-EPMC8278836 | biostudies-literature
| S-EPMC8667678 | biostudies-literature
| S-EPMC10638736 | biostudies-literature
| S-EPMC8950373 | biostudies-literature